Page last updated: 2024-10-24

busulfan and Myasthenia Gravis

busulfan has been researched along with Myasthenia Gravis in 2 studies

Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Djaldetti, M1
Pinkhas, J1
de Vries, A1
Kott, E1
Joshua, H1
Dollberg, L1
Rowland, LP1

Other Studies

2 other studies available for busulfan and Myasthenia Gravis

ArticleYear
Myasthenia gravis in a patient with chronic myeloid leukemia treated by busulfan.
    Blood, 1968, Volume: 32, Issue:2

    Topics: Aged; Autoimmune Diseases; Busulfan; Humans; Leukemia, Myeloid; Male; Myasthenia Gravis

1968
Immunosuppressive drugs in treatment of myasthenia gravis.
    Annals of the New York Academy of Sciences, 1971, Sep-15, Volume: 183

    Topics: Adult; Autoimmune Diseases; Azathioprine; Blood Cell Count; Busulfan; Cyclophosphamide; Female; Huma

1971